Celldex Therapeutics, Inc. (NASDAQ:CLDX) continues to predict that METRIC enrollment will be finalized by the close of the third quarter of 2017. It is a Phase IIb randomized pilot trial of glembatumumab vedotin in folks with metastatic triple negative breast cancer.
Celldex posted that Phase II study of glembatumumab vedotin has been permitted for oral presentation at imminent ASCO event. The updated statistics from the Phase II trial will be showcased at the ASCO Annual Meeting planned next month.
Enrollment recently finalized in the glembatumumab varlilumab and vedotin trial, with data from this trial anticipated in this year. Registration are current in the glembatumumab vedotin and checkpoint inhibitor trial in folks who failed checkpoint therapy, a population with obstructive treatment alternatives.
Celldex posted that Phase I trial of varlilumab and Opdivo® has been permitted for presentation at ASCO. The revised data from this Phase 1 trial will be presented imminent month in a presentation at the ASCO Yearly Meeting. This Phase II portion of the trial comprises cohorts in different types of cancer, counting ovarian cancer, colorectal cancer, and few more. The company is in the process of registering patients for the respective trial.
Celldex intends to close enrollment across all cohorts in the planned Phase II portion of the study in the first quarter of next year and will work together with Bristol-Myers Squibb to reveal data from the trial at an upcoming medical meeting. Data from the Phase I trial of varlilumab for treatment of solid tumors was mentioned in the Journal of Clinical Oncology.
The company reported that enrollment for Phase 1 trial of CDX-0158 is ongoing. This dose escalation trial in folks with advanced refractory GIST and KIT-positive tumors is planned to know MTD, suggest a dose for next trial and confirm CDX-0158 safety profile.